Flavored Electronic Cigarette Vape featured a draw-activated firing mechanism. Pre-filled e juice, small in size, easily put in pocket, Never worry about leakage, more sanitary, does not breed bacteria, it is a perfect pod device for those who are always on the go.
This disposable vape pen built in a 400mAh, 2ml 2% E-liquid, providing 600 puffs. it has six attractive flavors: Tobacco, Ice Cream, Cool Mint, A blend of Mango and Pomelo, Ice Green Bean.
Shenzhen Axiswell Technology Co., Ltd is a manufacturer of no leak electronic cigarette vape with R&D, production and sales team. Our star products are disposable vape pen, closed pod system, vape pods. Our MOQ is low and we provide OEM/ODM service. We understand good taste and reasonable pricing are important for long term cooperation between us and clients. We wish to cooperate with every clients no matter big quantity or small quantity, reaching win-win outcome!
e cigs,disposable e cig,disposable e-cig,disposable electronic cigarette vape,electronic mini cigarette Shenzhen Axiswell Technology Co., Ltd , https://www.medhealthycare.com
Researchers at the University of California and other institutions in the United States reported that they analyzed the condition and genetic information of more than 300 NSCLC patients and found that the activity of 14 genes in the patient can help predict the risk of death after treatment. .
To confirm the effectiveness of this method, the researchers then conducted confirmatory tests on more than 1,000 patients. The results showed that patients with a low risk of death were those whose genetic analysis showed a survival rate of 74% within 5 years of follow-up observations; those with genetic tests that showed moderate mortality risk had a survival rate of 57%; and those whose genetic tests showed a high risk of death. The survival rate is only 44%.
Researchers say that this genetic test can help determine if patients should receive additional chemotherapy. In the early stage of lung cancer treatment, only the method of surgical removal of the tumor is generally used for treatment. However, some patients often have hidden cancer cells in their bodies, resulting in postoperative cancer recurrence. Patients with high risk of death are mostly of this type.
For this type of patient, chemotherapy can be used to kill hidden cancer cells. However, studies have shown that for the entire patient population, the use of chemotherapy after surgery does not significantly improve survival. Because of the strong side effects of chemotherapy, those who do not need chemotherapy will also suffer. With these genetic tests, doctors can identify those patients who are at high risk of death and perform additional chemotherapy differently.
New Gene Detection Method Helps to Assess the Risk of Death in Lung Cancer Patients
A new issue of the British medical journal The Lancet published a report saying that U.S. researchers have developed a set of genetic testing methods that can roughly determine the risk of death from lung cancer patients. After identifying patients with a higher risk of death, they can take measures. Additional chemotherapy and other means to help treat.